Live Breaking News & Updates on Burke Therapeutics

Stay updated with breaking news from Burke therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Purple Biotech : NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors (Form 6-K)


Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer
REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the tr ....

United States , South Korea , Gil Efron , Bertrandc Liang , Megan Humphreys , Alberto Bessudo , Chuck Padala , Exchange Commission , Company Contact , Purple Biotech Ltd , California Cancer Associates For Research Excellence , Drug Administration , Bristol Myers Squibb , Coeptis Pharmaceuticals , Minimal Adverse Events , Initial Clinical Data , Ongoing Phase , Advanced Solid , Response Observed , Refractory Gastroesophageal Junction , Purple Biotech , California Cancer Associates , Chief Medical Officer , Burke Therapeutics , Looking Statements , Safe Harbor ,

Purple Biotech Appoints Seasoned Biopharmaceutical Industry


Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
May 19, 2021 07:00 ET
| Source:
Purple Biotech Ltd.
Purple Biotech Ltd.
Tel Aviv, ISRAEL
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.
“We are excited to welcome Suzana to our Board of Directors,” said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. “Ms. Nahum-Zilberberg has extensive experience in senior leadership positions at several leading biopharmaceutical companies.  As we continue to expeditiously advance CM ....

South Korea , Tel Aviv , Eric Rowinsky , Suzana Nahum Zilberberg , Teva Pharmaceuticals Industries , Nextferm Technologies Ltd , Asian International Executive Program , Purple Biotech Ltd , Human Xtention Ltd , Tel Aviv Stock Exchange , Bristol Myers Squibb , Tel Aviv University , Coeptis Pharmaceuticals , Purple Biotech , Vice Chairman , Biolight Life Science , Human Xtention , Vice President , Certified Director , International Executive , Burke Therapeutics , Nasdaq Ppbt , Purple Biotech Ltd , தெற்கு கொரியா , தொலைபேசி அவிவ் , தேவா மருந்துகள் தொழில்கள் ,